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Abstract 
Background: Blood prostate‑specific antigen (PSA) levels are widely used as diagnostic biomarkers for prostate 
cancer. Lateral‑flow immunoassay (LFIA)‑based PSA detection can overcome the limitations associated with other 
methods. LFIAbased PSA detection in clinical samples enables prognosis and early diagnosis owing to the use of 
high‑performance signal reporters.
Results: Here, a semiquantitative LFIA platform for PSA detection in blood was developed using Au–Ag nanoparti‑
cles (NPs) assembled on silica NPs (SiO2@Au–Ag NPs) that served as signal reporters. Synthesized SiO2@Au–Ag NPs 
exhibited a high absorbance at a wide wavelength range (400–800 nm), with a high scattering on nitrocellulose 
membrane test strips. In LFIA, the color intensity of the test line on the test strip differed depending on the PSA 
concentration (0.30–10.00 ng/mL), and bands for the test line on the test strip could be used as a standard. When 
clinical samples were assessed using this LFIA, a visual test line with particular color intensity observed on the test 
strip enabled the early diagnosis and prognosis of patients with prostate cancer based on PSA detection. In addition, 
the relative standard deviation of reproducibility was 1.41%, indicating high reproducibility, and the signal reporter 
showed good stability for 10 days.
Conclusion: These characteristics of the signal reporter demonstrated the reliability of the LFIA platform for PSA 
detection, suggesting potential applications in clinical sample analysis.
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Background
Prostate cancer (PCa) is the second most common can-
cer in men worldwide and the fifth leading cause of 
cancer-related death [1]. PCa can be cured by radical 
prostatectomy or radiation treatment (RT) during early 
stages; thus, early diagnosis is very important [2]. As the 
levels of prostate-specific antigen (PSA) increase after 
the onset of PCa, PSA is one of the most commonly used 
biomarkers for the diagnosis of PCa at the early stages, 
thereby reducing the mortality rates [3]. Based on the PSA 
levels, the following diagnoses are made: PSA ≤ 2.50 ng/
mL, normal; PSA of 4.00–10.00 ng/mL, early stage PCa; 
PSA ≥ 10  ng/mL, advanced stage [4]. In patients with 
2.50–4.00 ng/mL PSA, the status of PCa is not clear, and 
studies have emphasized that re-adjustment of the cutoff 
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value for PSA levels may be necessary [5–8]. Addition-
ally, after radical prostatectomy—the standard treatment 
for localized PCa—measurement of serum PSA levels is 
important for monitoring PCa recurrence [9]. In particu-
lar, in previous studies, a cutoff value of 0.30 ng/mL PSA 
after curative treatment was suggested for predicting bio-
chemical recurrence (BCR) after RT [10]. Accordingly, 
PSA levels after radical prostatectomy should be continu-
ously examined because the measurement of PSA levels 
after surgery is a relatively simple approach for diagnos-
ing BCR [11, 12]. However, healthy men who undergo 
PCa screening and patients with PCa who receive treat-
ment and need close follow-up based on their PSA levels 
are forced to undergo many expensive tests, resulting in 
a high burden [13–15]. Therefore, the development of an 
inexpensive, simple method for PSA measurement that is 
suitable for various applications, including assessment of 
prognosis, is essential.
Enzyme-linked immunosorbent assay (ELISA)—one 
of the most commonly used methods to detect PSA—is 
often used for the identification of biomarkers owing to 
its specificity, reproducibility, quantitative nature, and 
low detection limit (pg/mL to fg/mL level) [16]. However, 
PSA analysis using ELISA is time- and cost-intensive 
and requires well-trained technicians [17]. Lateral-flow 
immunoassay (LFIA)—which is based on test strips—has 
been widely recognized as an alternative to ELISA, owing 
to its economical and rapid analysis of biomolecules, 
such as PSA. LFIA is a low-cost, simple approach that 
can be employed on a large scale for clinical applications 
[18]. Moreover, LFIA enables visualized qualitative or 
semiquantitative analysis within 30  min [17]. For sensi-
tive detection, optical nanoparticles, such as colloid gold 
nanoparticles (AuNPs) or silver nanoparticles (AgNPs), 
which are easy to prepare and exhibit strong optical 
reactions and affinity for antibodies during conjugation 
are widely used in LFIA [19–21]. In particular, AuNPs 
are most often employed with LFIA for qualitative and 
semiquantitative analyses [22]. These AuNPs have several 
advantages, including a high extinction cross-section, 
colloidal stability, and affinity for antibodies in the visible 
spectrum as evidenced using surface plasmon resonance 
[23]. In LFIA, signal reporters, such as AuNPs conjugated 
to the detection antibody, are captured on the test line of 
the LFIA nitrocellulose (NC) membrane together with 
the target, thereby enabling visualization of the result. 
When colloid AuNPs were used as signal reporters for 
detecting PSA in LFIA, PSA detection was confirmed vis-
ually up to 0.50–3.00 ng/mL [24–27]. Although biosens-
ing is the primary use of AuNPs, many methods based 
on core/shell-type NPs, including conventional AuNPs 
for enabling the detection of PSA signals with high sen-
sitivity in LFIA have been reported. Xia et al. designed a 
colorimetric LFIA platform using core/shell-type Au@
Pt NPs as signal reporters in low-sensitivity mode and 
color-catalyzed Au@Pt NPs as signal reporters using a 
color molecule in the high-sensitivity mode for the detec-
tion of PSA [25]. Under optimized conditions, the naked 
eye detection limits of low- and high-sensitivity modes 
were 2  ng/mL and 20  pg/mL, respectively. However, 
detection of various concentrations of PSA using this 
LFIA platform is a complicated procedure owing to the 
separation of the low- and high-sensitivity modes. López 
et  al. developed silver and gold enhancement methods 
for LFIA, which enabled simple detection of PSA by the 
naked eye [24]. Under optimized conditions, the naked-
eye detection limit was 0.1 ng/mL when silver-enhanced 
AuNPs were used; this was five times lower than that 
for existing AuNPs. However, this method exhibits non-
specific binding in LFIA, and as it is difficult to handle 
samples via centrifugation, obtaining 100% recovery fol-
lowing antibody introduction is challenging.
In LFIA, the conditions used for the signal reporter 
should be efficient and reproducible, and there should 
be no nonspecific binding [28]. Signal reporters based 
on metal NPs assembled on silica NPs could overcome 
the problems of efficiency, reproducibility, and binding 
specificity owing to the ease of handling and surface 
modulation. The sizes of silica NPs can also be eas-
ily modulated, and modification of the surface is pos-
sible, thereby enabling the metal NPs to be introduced 
on the surface of silica NP [29]. Moreover, metal NP 
assembly on silica NPs could result in strong local-
ized surface plasmon resonance (LSPR) compared with 
single NPs [29]. Among metal NPs, Au–Ag alloy NPs 
exhibit stronger LSPR than single AuNPs or AgNPs and 
show various colors when the AuNP to AgNP ratio is 
altered [30, 31]. Based on these advantages of Au–Ag 
alloy NPs, our group recently reported nanostructures 
with Au–Ag NPs clustered on a silica core [31–33]. 
These nanostructures had a single broad absorbance 
peak, and the formation of optimized Au–Ag alloy NPs 
showed distinct colors depending on the target concen-
tration [34, 35].Accordingly, in this study, we developed 
an LFIA platform using Au–Ag alloy NPs assembled 
on silica NPs  (SiO2@Au–Ag NPs) for the visual analy-
sis of PSA.  SiO2@Au–Ag NPs were synthesized using 
an optimized synthesis method. Various concentrations 
of PSA were detected based on the color intensity of 
the test line in the test strip. By using this result as a 
standard, it was possible to semi-quantitatively detect 
PSA concentrations corresponding to those associated 
with early diagnosis and prognosis in the clinical sam-
ples. In addition, this LFIA platform with  SiO2@Au–Ag 
NPs was stable exhibited high reproducibility in terms 
of results for 10 days with signal intensity.
Page 3 of 10Kim et al. J Nanobiotechnol           (2021) 19:73  
Materials and methods
Materials
Tetraethyl orthosilicate (TEOS), 3-aminopropyltriethox-
ysilane (APTS), silver nitrate  (AgNO3), chloroauric acid 
 (HAuCl4), ascorbic acid (AA), polyvinylpyrrolidone (wt. 
10,000, PVP), sodium borohydride  (NaBH4), succinic 
anhydride, 11-mercaptoundecanoic acid (MUA), N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) 
hydrochloride, N-hydroxysulfosuccinimide (Sulfo-NHS) 
sodium salt, 2-(N-Morpholino)ethanesulfonic acid 
hydrate (MES hydrate), phosphate-buffered saline (PBS, 
pH 7.4), Tween 20, and ethanolamine were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Aqueous 
ammonium hydroxide  (NH4OH, 27%) and 1-methyl-
2-pyrrolidinone (NMP) were purchased from Daejung 
(Siheung, Korea). The backing card, nitrocellulose (NC) 
membrane, absorbent pad, cassette, monoclonal anti-
PSA antibody (mouse, anti-PSA Ab; cat. nos. 14801 and 
14,803), and goat anti-rabbit IgG Ab were purchased 
from Bore Da Biotech Co. Ltd. (Seongnam, Korea).
Synthesis of  SiO2@Au–Ag NPs
The  SiO2@Au–Ag NPs were synthesized as previ-
ously reported [36]. First, the  SiO2 NPs (approximately 
160  nm in diameter) were synthesized using the Stöber 
method [37]. The mixture containing of TEOS (1.6 mL) 
and  NH4OH (3  mL) in ethanol (40  mL) was stirred for 
20 h at 25 °C. The mixture was centrifuged at 8500 rpm 
for 15  min, and particles were washed several times 
using EtOH. For introducing the amine group onto 
the surface of silica NPs, the mixture containing  SiO2 
NPs (200  mg), absolute EtOH (4  mL), APTS (200 µL), 
and  NH4OH (40 µL) was mixed and stirred for 12  h at 
25 °C. Next, the mixture was centrifuged at 8500 rpm for 
15 min and washed several times using EtOH. For pref-
erentially introducing AuNPs (7 nm) onto the surface of 
aminated  SiO2 NPs  (SiO2@Au NPs), AuNPs were synthe-
sized using  HAuCl4 and  NaBH4 for 12 h with gentle shak-
ing at 25  °C. Consequently, AuNPs (7  nm in diameter), 
which had negatively charged ligands on their surfaces, 
were obtained after washing with centrifugation. Subse-
quently, aminated  SiO2 NPs (1 mg) resuspended in EtOH 
were mixed with AuNPs (1 mM) in deionized water, and 
the mixture was sonicated for 30  min and incubated 
overnight. The mixture was centrifuged at 8500 rpm for 
15  min and washed several times using EtOH. Thereaf-
ter, to create an Ag shell on the surface of  SiO2 NPs, the 
NPs (200 μg) were dispersed in 9.8 mL water containing 
20 μL of 10 mM ascorbic acid and 10 mg polyvinylpyrro-
lidone. This mixture was then stirred after the addition of 
10 mM  AgNO3 (20 µL) for 15 min at 25 °C to reduce  Ag+ 
ions to Ag. Next, the reduction steps were repeated with 
300 µM  AgNO3 (20 µL). The mixture was centrifuged at 
8500 rpm for 15 min, washed several times using EtOH, 
and dispersed in EtOH.
Conjugation of anti‑PSA Ab onto the surface of  SiO2@Au–
Ag NPs
For introducing the carboxyl groups onto the surface, 
 SiO2@Au–Ag NPs reconstituted in EtOH (200  μg/mL, 
1 mL) were mixed with 2 mM mercaptoundecanoic acid 
prepared in EtOH for 16  h at 25  °C. The mixture was 
washed several times with deionized water via centrifu-
gation at 13,000 rpm for 10 min, followed by redispersion 
in 50  mM MES buffer (pH 5.0). To activate the groups 
on the surface of carboxylated  SiO2@Au–Ag NPs, EDC 
hydrochloride (2 mg) and sulfo-NHS (2 mg) were added 
to carboxylated  SiO2@Au–Ag NPs prepared in 50  mM 
MES buffer, and the mixture was stirred for 30  min at 
25 °C. After removing the supernatant via centrifugation, 
NPs were dispersed in MES buffer.  SiO2@Au–Ag NPs 
were added to the anti-PSA Ab mixture (cat. no. 14803; 
1  mg/mL, 150 μL), and the mixture was stirred for 2  h 
at 25  °C. After centrifugation, anti-PSA Ab-introduced 
 SiO2@Au–Ag NPs in 50  mM MES were mixed with 
ethanolamine (3.2 μL), and the mixture was stirred for 
30  min at 25  °C. The mixture was then washed several 
times with 0.5% bovine serum albumin (BSA) prepared 
in phosphate-buffered saline (PBS) via centrifugation at 
13,000 rpm for 10 min and then redispersed in 0.5% BSA 
in PBS.
Synthesis of anti‑PSA Ab‑conjugated colloid AuNPs
AuNPs (15 nm diameter) were prepared as reported pre-
viously [38]. Water (99  mL) and 25  mM  HAuCl4·3H2O 
(1 mL) were mixed in an Erlenmeyer flask and stirred vig-
orously for 5 min at 100  °C. Subsequently, 3.3% sodium 
tricitrate in deionized water was added rapidly to the 
mixture, and the mixture was stirred for an additional 
1  h. Thereafter, the mixture was cooled to room tem-
perature, and its volume was adjusted to 100  mL with 
deionized water. Subsequently, the pH of the mixture was 
adjusted to 8.5 using polyvinylpyrrolidone (100 mg).
Thereafter, 2  mM AuNPs (1  mL) in deionized water 
was mixed with anti-PSA Ab (cat. no. 14803; 1 mg/mL, 
200 μL), and the mixture was incubated overnight at 4 °C. 
After completion of the reaction, the mixture was cen-
trifuged at 17,000 rpm for 15 min for sedimentation and 
dispersed in PBS containing 0.5% BSA.
Characterization of  SiO2@Ag@SiO2 NPs
Transmission electron microscopy (TEM) was performed 
using a LIBRA 120 (Carl Zeiss, Oberkochen, Germany). 
Field emission-scanning electron microscopy (FE-SEM) 
was performed using an SU-8010 instrument (Hitachi, 
Tokyo, Japan). UV–Vis extinction spectra were obtained 
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with an OPTIZEN POP instrument (Mecasys, Daejeon, 
Korea).
Preparation of test strips
The test strips comprised a backing card, NC mem-
brane, and absorbent pad (Additional file  1: Fig. S1). 
After assembling the NC membrane and absorbent pad 
on the backing card, anti-PSA Ab prepared in PBS (cat. 
no. 14801; 1 mg/mL) was sprayed on the test line, and the 
control line was sprayed with goat anti-rabbit IgG pre-
pared in PBS (1 mg/mL) using a dispenser. The strip was 
dried for approximately 24 h. Next, 0.1% BSA was applied 
and the assembly was dried for at least 1 day. Finally, the 
absorbent pad was assembled on the backing card. After 
cutting the strips to a width of 4 mm, the test strips were 
prepared.
Collection of clinical samples
Before starting this study, all clinical samples were 
obtained with written informed consent, and the study 
design was approved by the Seoul National University 
Bundang Hospital (IRB No. B 1711/432–302).
Analysis of colored test lines in the test strips
To measure the color intensity of the test line on the 
test strips, images of test strips were captured as 8-byte 
images using an ImageQuant LAS-4000 (GE Healthcare, 
Chicago, IL, USA).31 Captured images were analyzed 
using ImageJ ver. 1.53a (National Institutes of Health, 
Bethesda, MD, USA).
Stability test for  SiO2@Au–Ag NPs as signal report-
ers in LFIAnti-PSA Ab-conjugated  SiO2@Au–Ag NPs 
were stored in 0.5% BSA in PBS to evaluate stability for 
14  days. Every 2  days, stored anti-PSA Ab-conjugated 
 SiO2@Au–Ag NPs were mixed with clinical samples 
spiked with 0.54  ng/mL PSA, and LFIA was performed 
in three batches. After analysis, the test strip was checked 
visually, and the color intensity of the test line of the test 
strip was measured using ImageJ.
Results and Discussion
Synthesis of  SiO2@Au–Ag NPs
The process used for synthesizing Au–Ag alloy NPs 
assembled on silica NPs  (SiO2@Au–Ag NPs) is described 
in Fig.  1a.  SiO2 NPs (160  nm) were synthesized using 
the Stöber method (Fig.  1b(i)) [29]. Subsequently, the 
Fig. 1 Synthesis of  SiO2@Au–Ag NPs. a Synthesis procedure for  SiO2@Au–Ag NPs. b Transmission electron microscopy (TEM) images of (i)  SiO2 NPs, 
(ii)  SiO2@Au NPs, and (iii)  SiO2@Au–Ag NPs. c EDX mapping showing each component of  SiO2@Au–Ag NPs, including (i) Si atoms, (ii) Au atoms, and 
(iii) Ag atoms. (iv) Overlay image of all elements
Page 5 of 10Kim et al. J Nanobiotechnol           (2021) 19:73  
NP surfaces were modified to amine groups, and colloid 
AuNPs (7 nm) were introduced onto the  SiO2 NPs  (SiO2@
Au NPs, Fig. 1b(ii)). Silver ions on the surface of AuNPs 
were reduced, yielding  SiO2@Au–Ag NPs (Fig.  1b(iii)) 
[32]. The chemical compositions of the  SiO2@Au–Ag 
NP were investigated using energy dispersive spectros-
copy (EDX) mapping. The locations of the Si, Au, and Ag 
atoms in the  SiO2@Au–Ag NPs are shown in Fig.  1c(i–
iv). EDX revealed that both AuNPs and AgNPs were 
located on the surface of silica NPs. These results demon-
strated the successful fabrication of  SiO2@Au–Ag NPs.
Next, we investigated the characteristics of the synthe-
sized  SiO2@Au–Ag NPs. Figure 2a(i) shows the UV–vis 
absorption spectra for each sample during the synthe-
sis of  SiO2@Au–Ag NPs.  SiO2@Au NPs showed unique 
absorbance peaks at approximately 520  nm (compared 
with  SiO2 NPs), and  SiO2@Au–Ag NPs showed a wide 
absorbance band (400‒800 nm; compared with  SiO2@Au 
NPs) [36]. These results demonstrated that an Ag layer 
was formed on the surface of AuNPs immobilized on 
 SiO2 NPs. Figure 2a(ii) shows color images of  SiO2 NPs, 
 SiO2@Au NPs, and  SiO2@Au–Ag NPs (1 ×  1010 particles/
mL) dispersed in EtOH. Assembly of NPs is known to 
induce plasmon vibrations, which cause a color change 
[39]. Visually, because the band of the finally synthesized 
 SiO2@Au–Ag NPs exhibited a wide spectrum of absorb-
ance, it appeared dark brown in EtOH.
We also investigated the scattering effect of  SiO2@
Au–Ag NPs on light in the NC membranes of test strips. 
Normally, the band on the NC membrane absorbs and 
scatters light according to the plasmon properties of the 
signal reporter. As previously reported, a series of two 
consecutive 1/4 dilutions of  SiO2@Au–Ag NPs,  SiO2@
Au NPs, and colloid AuNPs (size: 15 nm, λabs,max: 520 nm) 
were prepared (Additional file  1: Fig. S3). The prepared 
samples were dropped by spotting on the circular NC 
membrane (6 mm), and visibility was confirmed based on 
the distribution of color spots according to NP dilution. 
Fig. 2 Characterization of  SiO2@Au–Ag NPs. a(i) UV–vis extinction spectra of  SiO2 NPs,  SiO2@Au NPs, and  SiO2@Au–Ag NPs. a(ii) Color image of  SiO2 
NPs,  SiO2@Au NPs, and  SiO2@Au–Ag NPs in EtOH solution. b(i) Scanned color image of the spots formed on the NC membrane (6 mm) with 3 μL 
suspension containing A  SiO2@Au–Ag NPs, B  SiO2@Au NPs, and C colloid AuNPs at different dilutions (1, 1/4, and 1/16). (b(ii)) Signal intensity based 
on the scattering effect of corresponding‑colored spots on the NC membrane. Error bars represent the standard deviations of the means for three 
batches of analyte measurements
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First, 3 μL of each sample was dropped onto the NC 
membrane and dried, and then the NC membrane was 
scanned. Figure  2b(i) shows an image of colored spots 
obtained upon applying a dilution (top to bottom). Upon 
visual analysis, the colored spots faded as the concentra-
tion of each sample decreased; when all signal reporters 
were diluted to 1/16, only the color intensity of  SiO2@
Au–Ag NPs was observed. When comparing the color 
intensity between all signal reporters,  SiO2@Au–Ag NPs 
showed the brightest signal compared with other sam-
ples at all dilutions (Fig. 2b(ii)). These results confirmed 
that  SiO2@Au–Ag NPs were suitable for use in the LFIA 
platform owing to their high scattering effect in the NC 
membrane of the test strips.
Changes in the color intensity of the test line according 
to the concentration of PSA in LFIA
To utilize  SiO2@Au-Ag NPs in the LFIA platform, the 
surface of  SiO2@Au-Ag NPs was modified at carboxyl 
groups using 11-mercaptoundecanoic acid. Next, the 
surface was activated using EDC/sulfo-NHS, and anti-
PSA Abs were conjugated onto the surface. The UV-Vis 
absorption spectrum of anti-PSA Ab-conjugated  SiO2@
Au-Ag NPs was preserved after conjugation of anti-PSA 
Abs (Additional file 1: Fig. S2). The working principle of 
the LFIA is shown in Fig. 3a. The test strip comprised an 
absorbent pad and an NC membrane; after assembling 
the components, the dipstick method was used for 
PSA and anti-PSA Ab-conjugated  SiO2@Au-Ag NPs in 
96-well plates. The results showed that PSA and anti-
PSA Ab-conjugated  SiO2@Au-Ag NPs formed complexes 
in the wells, and test strips were then dipped in the cor-
responding wells. After 15 min, the test line on the test 
strip turned dark brown, a phenomenon that could be 
confirmed visually owing to the interaction between the 
complex and the capture antibody.
Fig. 3b and c show the results of concentration-specific 
analysis of PSA using the newly developed LFIA plat-
form. Analysis was performed at PSA concentrations 
ranging from 0 to 300.00 ng/mL. As the concentration of 
PSA increased, more immune complexes were formed at 
the test line, and the brown color of the test line became 
darker, as expected. At a concentration of 0.30 ng/mL, the 
test line could be observed with the naked eye (Fig. 3b). 
Additional file 1: Fig. S4 shows scanning electron micros-
copy (SEM) images of the test line on test strips (at PSA 
= 0 ng/mL and PSA = 300.00 ng/mL).  SiO2@Au-Ag NPs 
bound to the NC membrane through PSA were clearly 
different from the test line for 0 ng/mL in SEM. When 
more PSA antigen-SiO2@Au-Ag NPs complexes were 
captured on the test line, the signal intensity of the test 
line increased as the concentration of PSA increased 
(Fig. 3c). Analysis of the calibration curves based on the 
signal intensity revealed that the limit of detection (LOD) 
Fig. 3 Schematic illustration of PSA detection using the lateral flow immunoassay (LFIA) platform with  SiO2@Au–Ag NPs as a signal reporter. 
b Color. c Schematic of early diagnosis and prognosis detection by measuring the signal intensity [i: no recurrence (PSA < 0.30 ng/mL), ii: 
recurrence (0.30–1.00 ng/mL PSA), iii: no cancer (1.00–3.00 ng/mL PSA), iv: early‑stage disease (3.00–10.00 ng/mL PSA), and v: late‑stage disease 
(PSA > 10.00 ng/mL)]. Error bars represent the standard deviations of the means for three batches of analyte measurements
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was 0.20 ng/mL. Based on these semiquantitative results 
and PSA concentrations of 1.00–10.00 and 0.30–1.00 ng/
mL, the color intensity of the test line on the test strip 
was used as a standard for early diagnosis. Specifically, 
normal status was indicated as a signal in the 1.00–3.00 
ng/mL PSA section of the test strip; early-stage disease 
was indicated as a signal in the 3.00–10.00 ng/mL PSA 
section of the test strip; and late-stage disease was indi-
cated as a signal at greater than 10.00 ng/mL PSA. In 
addition, to monitor for recurrence, biochemical recur-
rence was indicated as a signal in the 0.30–1.00 ng/mL 
PSA section, whereas no recurrence was indicated as a 
signal at less than 0.30 ng/mL PSA. As a standard, a band 
showing different colors dependent on the concentration 
at the test line was sufficient to distinguish each stage, 
and the low sensitivity was suitable for use in patient 
prognosis. For comparison of the detection ability of the 
 SiO2@Au-Ag NPs, existing colloid AuNPs conjugated to 
anti-PSA Ab were evaluated, and the LODs of these two 
signal reporters were calculated at the same concentra-
tion of PSA (Additional file 1: Fig. S5). The band on the 
test line could be observed at a PSA concentration of 
1.00 ng/mL when colloid AuNPs were used as the signal 
reporter. Moreover, the color intensity difference accord-
ing to the PSA concentration for each strip using colloid 
AuNPs was not greater than that of  SiO2@Au-Ag NPs. 
The LOD determined from the standard deviation was 
0.82 ng/mL for colloid AuNPs. Based on the calculated 
LODs,  SiO2@Au-Ag NPs were approximately four times 
more sensitive than colloid AuNPs and  SiO2@Au NPs, 
and these results demonstrated the high performance of 
the prepared  SiO2@Au-Ag NPs for PSA detection with 
LFIA. Additionally, these results demonstrated the appli-
cability of this approach as a standard.
Clinical validation of LFIA for PSA detection
PSA detection in clinical samples is essential for assess-
ing the performance and practical applicability of the 
LFIA platform. Therefore, we evaluated the applicabil-
ity of LFIA with the standard obtained from the previ-
ous results using  SiO2@Au-Ag NPs for PSA detection 
in clinical samples. Previously, clinical samples (1: < 0.01 
ng/mL, 2: 0.80 ng/mL, 3: 2.01 ng/mL, 4: 5.61 ng/mL, and 
5: 12.84 ng/mL) were prepared by selecting samples cor-
responding to different sections of the standard obtained 
from the above results. When applying actual clinical 
samples to the LFIA platform, the amount of clinical 
sample used was 30 μL, which is less than that used for 
conventional enzyme-linked immunosorbent assays [40]. 
Clinical samples with PSA concentrations correspond-
ing to each section were used, and PSA samples with 
PSA concentrations of less than 0.01 ng/mL were used 
as negative controls. As shown in Fig. 4a, except for the 
negative control (strip 1), all other PSA-positive samples 
showed bands on the test line. When measuring the color 
intensity of the band on the test line for each strip, the 
color intensities were correlated with the concentration 
of PSA. Additionally, when visually comparing the results 
with the color intensity of the standard, we confirmed 
that the bands produced by the clinical samples were 
within the appropriate section of the test strip (Fig. 4b). 
Thus, PSA in clinical samples was visually different from 
that in negative control samples, even at low concentra-
tions, when using the prepared assay system.
Fig. 4 Application of clinical samples with  SiO2@Au–Ag NPs as a signal reporter by comparison with the standard in LFIA. a Color image test line (T) 
on each test strip (i: PSA standard (S), ii PSA < 0.01 ng/mL (1), iii: 0.80 ng/mL PSA (2), iv: 2.01 ng/mL PSA (3), v: 5.61 ng/mL PSA (4), and vi: 12.84 ng/mL 
PSA (5). b Measurement of signal intensity using clinical samples with the standard in the LFIA platform. Error bars represent standard deviations of 
the means for three batches of analyte measurements
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In the LFIA using  SiO2@Au-Ag NPs, because the visual 
LOD of the test line was 0.30 ng/mL PSA, a clinical sam-
ple with a PSA concentration of 0.32 ng/mL was applied 
to the LFIA to confirm the visual LOD in clinical samples. 
Importantly, the intensity at the test line appeared similar 
to that in the standard but was slightly higher when the 
results were compared using ImageJ (Additional file  1: 
Fig. S6). Thus, these results showed that the visual LOD 
was consistent in clinical samples. In this study, complete 
quantitative analysis was difficult using the developed 
LFIA platform. However, the platform was suitable for 
screening because the stage of progression could be dis-
tinguished through analysis of the color intensity during 
early diagnosis and prognosis [41].
Reproducibility and stability tests using  SiO2@Au‑Ag NPs 
in the LFIA platform
To validate our clinical sample analysis, we assessed 
the reproducibility of LFIA for PSA detection in serum 
using  SiO2@Au-Ag NPs and the storage stability of 
 SiO2@Au-Ag NPs as the signal reporter for LFIA appli-
cation. First, the reproducibility test was performed 
with 10 batches of clinical samples (0.53 ng/mL PSA) 
simultaneously. As shown in Fig. 5a(i), the color inten-
sity of the test line on the test strip was visually con-
stant for samples with the same PSA concentration. 
The signal intensity of the test line on each test strip 
was analyzed using ImageJ (Fig. 5a(ii)), and the relative 
standard deviation (RSD) of the color intensity of the 
test line for the 10 batches was 1.41%, indicating high 
reliability [42]. Therefore, these findings confirmed the 
reproducible performance of the developed platform 
for the detection of PSA. Second, storage stability tests 
were conducted using  SiO2@Au-Ag NPs stored in 0.5% 
BSA for the evaluation of clinical samples (0.56 ng/mL 
PSA) with the developed LFIA platform. Visually, the 
color of the test line in the test strip was almost con-
stant until approximately 10 days (Fig.  5b(i)). Similar 
results were observed upon analysis of the signal inten-
sity of the test line using ImageJ (Fig. 5b(ii)). The RSD 
of the signal intensity was 0.96% for day 10, indicating 
high reliability. Based on these results, we concluded 
that the developed platform had high reproducibility in 
terms of performance, even after storage for 10 days.
Fig. 5 a Test of reproducibility using  SiO2@Au–Ag NPs as a signal reporter with clinical samples (0.53 ng/mL PSA) in LFIA. (i) Color images and (ii) 
measurement of signal in‑tensity. b Test of stability using  SiO2@Au–Ag NPs with clinical sample (0.56 ng/mL PSA) in LFIA. (i) Color image and (ii) 
measurement of signal intensity. Error bars represent standard deviations of the means for three batches of analyte measurements
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Conclusion
Herein, we described a visual LFIA with  SiO2@Au-Ag 
NPs as detection signal reporters for semiquantitative 
detection of PSA in clinical samples.  SiO2@Au-Ag NPs 
exhibited a broad absorption spectrum of 400–800 nm 
as Au-Ag NPs were successfully assembled onto  SiO2 
NPs, and the scattering effect was significantly superior 
to that of  SiO2@Au NPs and colloid AuNPs. In addition, 
in the LFIA platform for PSA detection, we observed a 
color change that depended on the PSA concentration, 
and these results were used as a standard for semiquan-
titative analysis. Furthermore, PSA could be visually 
detected in clinical samples, and the color intensity 
corresponded to the PSA concentration, providing a 
platform for semiquantitative analysis and enabling 
diagnosis and prognosis. In addition, in reproducibility 
tests using clinical samples, the RSD for 10 batches was 
1.41%, indicating high reproducibility, and the results 
of stability tests using  SiO2@Au-Ag NPs in 0.50% BSA 
solution showed that the signal was almost constant 
after storage for 10 days. Overall, these results showed 
the possibility of application of this approach for early 
diagnosis and prognosis by comparison with the stand-
ard. The developed LFIA platform showed limited abil-
ity for quantitative analysis; however, the system could 
be used for quantitative analysis of more advanced 
particles. Furthermore, our findings demonstrated the 
applicability of the method for analyzing other clinical 
samples that require semiquantitative analysis.
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